Edding Genor Group Holdings Limited (HKG: 6998) announced a supplemental agreement and termination agreement with Napeptide (Qingdao) Biopharmaceutical Co., Ltd., restructuring their siRNA collaboration originally established in September 2023 and May 2024. The revised terms expand Edding Genor’s ANGPTL3 asset to global rights while terminating development of two other preclinical siRNA programs.
Restructuring Overview
Original Agreement
Date
Scope
Initial Licensing
Sept 2023
Exclusive rights to 2 preclinical siRNA assets
Additional In‑License
May 2024
Third siRNA asset added
Revised Terms (March 2026)
Adjustment
Detail
① ANGPTL3 Expansion
Territorial scope expanded to global rights
Patent Rights
Edding Genor obtains global patent rights to ANGPTL3 molecule
Platform Co‑Ownership
GalNAc delivery technology co‑owned with Need Pharma
② Termination
Collaboration on 2 other preclinical siRNA assets ended
Strategic Implications
ANGPTL3 Focus: The global rights expansion signals Edding Genor’s strategic prioritization of the ANGPTL3 siRNA—a validated cardiovascular target (see: vupanorsen, pelacarsen) with blockbuster potential in dyslipidemia and cardiovascular risk reduction.
GalNAc Platform Control:Co‑ownership of GalNAc (N‑acetylgalactosamine) delivery technology—the industry standard for liver‑targeted siRNA—provides long‑term competitive moat and platform expansion capabilities for additional liver‑expressed targets.
Portfolio Rationalization:Termination of two preclinical assets reflects disciplined capital allocation, focusing resources on the highest‑potential program rather than spreading investment across multiple early‑stage candidates.
Global Ambition:Worldwide patent rights position Edding Genor for US/EU clinical development and multinational partnership, elevating the company from China‑focused to global biotech contender.
ANGPTL3 Market Context
Factor
Impact
ANGPTL3 Biology
Regulates triglyceride and LDL metabolism; loss‑of‑function mutations associated with cardiovascular protection
GalNAc‑conjugated siRNA enables quarterly dosing with deep, durable lipid lowering—superior to monthly antibody alternatives
Edding Genor Positioning
Global rights + GalNAc co‑ownership creates integrated development capability; potential for first‑in‑class or best‑in‑class ANGPTL3 siRNA
Forward‑Looking Statements This brief contains forward‑looking statements regarding ANGPTL3 IND filing timelines, global clinical development strategy, and GalNAc platform monetization potential. Actual results may differ due to risks including competitive ANGPTL3 program advancement, siRNA manufacturing scale‑up, and partnership negotiation outcomes for ex‑China commercialization.-Fineline Info & Tech
By Fineline Cube